Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Novo Nordisk A/S
Sponsor

Novo Nordisk A/S

Denmark Novo Alle 1, 2880, Denmark

About the sponsor

Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.

  • HbA1c reduction
  • Insulin icodec
  • Oral semaglutide
  • Diabetic retinopathy

Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.

About Specializations

Novo Nordisk A/S runs clinical trials in conditions such as Type 2 diabetes mellitus, Obesity, Overweight, Sickle cell disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

82 clinical trials

Type 2 diabetes mellitus+1

Recruiting

Study of once weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes and chronic kidney disease on basal insulin

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obstructive sleep apnoea syndrome

Recruiting

A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obstructive sleep apnoea syndrome

Recruiting

Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Recruiting

Efficacy and safety of weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes not controlled by diet and exercise

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Recruiting

Efficacy and safety of zenagamtide versus semaglutide in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitors

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Acquired haemophilia

Recruiting

Evaluating denecimig as bleeding prophylaxis in adults with acquired haemophilia A

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Denecimig
  • Sponsor:Novo Nordisk A/S

Obesity

Recruiting

A study of NNC0638-0355 to evaluate safety, tolerability and weight loss with multiple doses in adults with obesity or overweight

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:NNC0638-0355
  • Sponsor:Novo Nordisk A/S

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.